Open AccessHypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review
Author(s) -
Zhengyang Tang,
XiuHai Ji,
Guanghui Zhou,
Ruhua Chen,
Yan Fu,
Hui Ding
Publication year - 2021
Publication title -
anti-cancer drugs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.651
H-Index - 93
eISSN - 1473-5741
pISSN - 0959-4973
DOI - 10.1097/cad.0000000000001244
Subject(s) - afatinib , medicine , epidermal growth factor receptor , nausea , lung cancer , oncology , cancer , erlotinib
Side effects of afatinib are a problem in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of afatinib-induced hypotension. An 81-year-old man with NSCLC had an epidermal growth factor receptor-positive genotype with the p.L861Q mutation in exon 21. He was administered afatinib (40 mg/day) as anticancer therapy. Hypotension occurred twice after afatinib initiation. He suffered from dizziness and nausea. Blood pressure gradually returned to normal after afatinib cessation. Clinicians should be aware of hypotension in patients with NSCLC after afatinib initiation.